Peptide Synthesis Market to Reach US$ 2,268.16 Million by 2033 at 11.4% CAGR; Rising Demand for Therapeutic Peptides Drives Growth - Key Players: Bachem, Thermo Fisher Scientific, Merck

The global peptide synthesis market reached US$ 780.00 million in 2023, increased to US$ 860.99 million in 2024, and is expected to reach US$ 2,268.16 million by 2033, growing at a CAGR of 11.4% during the forecast period 2025-2033. The market is witnessing strong growth driven by rising demand for therapeutic peptides, peptide-based vaccines, and specialized biologics across oncology, metabolic disorders, and infectious disease applications. Expanding biopharmaceutical pipelines and increasing investment in peptide-focused drug development are further accelerating market expansion.

Market growth is supported by the increasing complexity of peptide therapeutics, which is driving adoption of both solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) technologies. Innovations in automated peptide synthesizers, high-throughput purification systems, and continuous-flow solution-phase processes are improving production efficiency, scalability, and yield while reducing costs. Strategic investments by key players, such as CordenPharma's €1 billion expansion in SPPS capacity and Cambrex's advancement of LPPS technologies, are strengthening manufacturing capabilities and broadening access to high-quality peptides. Together, technological advancements, rising chronic disease prevalence, and robust R&D activity are positioning peptide synthesis as a critical and rapidly expanding segment of the global biopharmaceutical industry.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/peptide-synthesis-market?sai-v

The peptide synthesis market is the sector that develops and supplies technologies, reagents, and services for the production of peptides used in pharmaceuticals, biotechnology, and research applications.

Key Developments
✅ October 2025: U.S. pharmaceutical and biotechnology companies implemented solid-phase and liquid-phase peptide synthesis methods for production of research-grade, clinical-grade, and commercial peptides used in approved drugs and ongoing clinical trials.

✅ September 2025: European contract development and manufacturing organizations (CDMOs) installed automated peptide synthesizers and validated purification workflows to meet regulatory requirements for GMP peptide manufacturing.

✅ August 2025: Asia-Pacific manufacturers produced peptide active pharmaceutical ingredients (APIs) for therapeutic applications including metabolic disorders, oncology, and infectious diseases.

✅ July 2025: Global peptide synthesis providers applied in-process analytical techniques such as HPLC and mass spectrometry for peptide identity, purity, and batch release testing.

✅ May 2025: North American academic and industrial research laboratories utilized custom peptide synthesis services for biomarker research, assay development, and drug target validation.

✅ March 2025: Peptide synthesis technologies were used globally for production of linear peptides, cyclic peptides, and modified peptides for pharmaceutical and diagnostic use.

Mergers & Acquisitions
✅ November 2025: A U.S.-based life sciences company completed acquisition of a peptide synthesis service provider to integrate peptide manufacturing into its existing pharmaceutical services portfolio.

✅ August 2025: A European peptide manufacturer entered a commercial agreement with a pharmaceutical company for GMP-compliant peptide production.

✅ June 2025: An Asia-Pacific peptide synthesis company was acquired by a multinational biopharmaceutical organization, transferring ownership of peptide synthesis assets and customer contracts.

Key Players
Bachem | Thermo Fisher Scientific | Merck | GenScript | PolyPeptide Group | Almac Group | Kaneka Eurogentec | Biosynth | BCN Peptides | CPC Scientific

Key Highlights
Bachem - Holds a share of 22.4 percent: Global leader in peptide manufacturing with strong capabilities in active pharmaceutical ingredients, contract development, and large scale commercial production.

Thermo Fisher Scientific - Holds a share of 18.1 percent: Provides end to end peptide synthesis, analytical services, and contract manufacturing supporting pharmaceutical and biotechnology clients.

Merck - Holds a share of 16.3 percent: Strong presence in peptide synthesis reagents, custom manufacturing, and life science services for drug development.

PolyPeptide Group - Holds a share of 13.7 percent: Specializes in contract development and manufacturing of therapeutic peptides for clinical and commercial applications.

GenScript - Holds a share of 10.5 percent: Focuses on custom peptide synthesis and biologics services supporting research and early stage drug discovery.

Almac Group - Holds a share of 7.2 percent: Offers peptide development, analytical testing, and GMP manufacturing for pharmaceutical companies.

Kaneka Eurogentec - Holds a share of 5.4 percent: Provides custom peptides and bio reagents for research, diagnostics, and clinical applications.

Biosynth - Holds a share of 3.4 percent: Supplies specialty peptides and fine chemicals for life science research and diagnostics.

BCN Peptides - Holds a share of 1.6 percent: Focuses on GMP peptide manufacturing for clinical trials and niche therapeutic applications.

CPC Scientific - Holds a share of 1.4 percent: Provides custom peptide synthesis and manufacturing services primarily for research and early stage development.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=peptide-synthesis-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising demand for peptides in therapeutic, diagnostic, and research applications.

- Growing prevalence of chronic diseases and demand for peptide-based drugs in oncology, metabolic disorders, and infectious diseases.

- Advancements in peptide synthesis technologies including solid-phase peptide synthesis (SPPS) and flow chemistry.

- Expansion of peptide therapeutics pipelines and increased clinical research activity.

- Increasing use of peptides in vaccine development, biomaterials, and cosmeceuticals.

- Rising investments by pharmaceutical, biotechnology, and contract research organizations (CROs).

- Supportive regulatory frameworks and faster approval pathways for peptide-based drugs.

Industry Developments
- Launch of automated and high-throughput peptide synthesizers and purification systems.

- Development of novel chemical reagents and resins improving synthesis efficiency and yield.

- Growing partnerships between peptide manufacturers, biotech firms, and research institutions.

- Expansion of peptide synthesis services offered by CDMOs and CROs.

- Introduction of scalable platforms for longer and complex peptide sequences.

- Increasing mergers, acquisitions, and strategic investments in peptide synthesis technology providers.

- Integration of AI and software tools for design, optimization, and process control.

Regional Insights
North America - 42% share: "Driven by strong biotech research infrastructure, high pharmaceutical R&D investment, and widespread adoption of advanced synthesis technologies."

Europe - 29% share: "Supported by robust academic research, growing clinical peptide programs, and presence of key peptide synthesis manufacturers."

Asia Pacific - 24% share: "Fueled by expanding pharmaceutical and biotech sectors, increasing healthcare R&D, and rising contract synthesis demand."

Latin America - 3% share: "Boosted by improving research capabilities, growing academic collaborations, and emerging synthesis service uptake."

Middle East & Africa - 2% share: "Driven by growing investments in life sciences research and gradual adoption of peptide synthesis technologies."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/peptide-synthesis-market?sai-v

Key Segments
By Technique
Solid phase synthesis dominates the market owing to its high efficiency, scalability, and ability to produce high-purity products with improved automation and reproducibility. This technique is widely adopted in large-scale production and research applications due to reduced processing time and lower contamination risk. Solution phase synthesis holds a significant share, supported by its flexibility and suitability for smaller-scale synthesis and complex molecular structures. The hybrid approach is gaining traction as it combines the advantages of both solid and solution phase techniques, enabling improved yield, flexibility, and cost efficiency for specialized applications.

By Product Type
Equipment represents a substantial segment, driven by continuous advancements in synthesis platforms, automation technologies, and growing investments in laboratory infrastructure. Reagents and consumables account for a major share of recurring revenue, supported by frequent usage in synthesis processes and expanding research activities. Services are witnessing steady growth as organizations increasingly outsource synthesis, customization, and analytical services to specialized providers to reduce costs and accelerate development timelines.

By Application
Therapeutic applications dominate the market, fueled by rising demand for advanced therapeutics, increasing R&D activity, and a growing pipeline of novel drug candidates. The diagnostics segment is expanding steadily, supported by the use of synthesized molecules in biomarker detection and assay development. Research applications continue to grow due to increasing academic and industrial research initiatives, government funding, and ongoing innovation in life sciences and biotechnology.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.